Akebia Therapeutics, INC 8-K filings
NASDAQ
Akebia Therapeutics has further extended the separation dates for its Chief Operating Officer and Senior Vice President, Chief Legal Officer and Secretary.
NASDAQ
8-K: Akebia Therapeutics Secures $55 Million Loan Facility with Kreos Capital, Refinances Existing Debt
Akebia Therapeutics has entered into a new $55 million term loan facility with Kreos Capital, which includes an initial $37 million tranche and the refinancing of its previous debt with Pharmakon.